R01 Grant funded by NIAID
Temporal Phenotypes and Risk Models for the Post-COVID Syndrome and its sub-types
Created Jul 21, 2022 - Last updated: Jul 20, 2022
We just received an R01 award from the National Institute of Allergy and Infectious Diseases to study the post-acute sequelae of COVID-19 (PASC).
For millions of people infected with COVID-19, recovery from the acute phase of the infection will be grueling with a debilitating second act. A collection of persistent physical (e.g., fatigue, dyspnea, chest pain, cough), psychological (e.g., anxiety, depression, post-traumatic stress disorder), and neurocognitive symptoms (e.g., impaired memory and concentration) can appear and last for weeks or months in patients after acute COVID- 19, impeding their ability to function normally and costing the U.S. economy billions of dollars annually in medical bills and lost incomes. Still, little is known about the post-acute sequelae of COVID-19, the extent and causes of its lingering health issues, which patients might develop them, and how to address them. We seek to leverage electronic health records (EHRs) data from 7 hospital systems across the U.S. to develop and validate a novel framework for studying evolving temporal phenotypes of the post-acute sequelae of COVID-19.